Status:
UNKNOWN
Proof of Concept Study in Patients With Short Bowel Syndrome
Lead Sponsor:
9 Meters Biopharma, Inc.
Conditions:
Short Bowel Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a Phase I/II. proof of concept, open label, two-dose, dose escalation study of NM-002 in adult patients with SBS who previously responded to exenatide. NM-002 is planned to be administered twi...
Detailed Description
During a baseline period, all subjects will remain on their current prescription for administration of PS. Between Days -7 to -5 patients who have met initial screening criteria will return to the cli...
Eligibility Criteria
Inclusion
- Males and females with SBS secondary to surgical resection of small intestine, with or without an intact colon
- 18-75 years of age at the time of screening
- Female subjects must be postmenopausal (at least 2 years prior to dosing) or surgically sterile or agree to use an acceptable form of birth control from screening until 30 days after last dose. If oral contraceptives are used, Subject must have been on a stable dose for ≥6 months. (See below, "Participation of Women", for additional detail.)
- Male subjects must agree to use an acceptable form of birth control during the study and for 90 days after the last dose. Male subjects may not donate sperm for 90 days after last dose.
- At least 6 months since last surgical bowel resection
- Patients may be on Parenteral support (nutrition and/or fluid and electrolytes \[PS\]) for at least some of their nutritional needs.
- If on PS, stable administration of PS volume for 1 month (±20% vol) prior to enrollment.
- Able to ingest solid foods and drink
- Willing to adhere to a defined oral intake of fluids on certain days as required by protocol and based on the individual's routine daily consumption.
Exclusion
- Positive results on the HIV, Hepatitis, or drug screens.
- Pregnancy or lactation
- Body mass index \<18 or \>30 kg/m2
- Clinically significant intestinal adhesions and/or chronic abdominal pain
- Active Crohn's disease or IBD (as evaluated by standard procedures employed by the investigator/institution). If in remission, must be ≥12 weeks of remission prior to enrollment.
- If on chronic systemic narcotics, the patient must have been on a stable dose for \>12 weeks
- Inflammatory bowel disease patients who have NOT been on a stable drug treatment regimen for at least the past 3 months.
- Visible blood in the stool within the last 3 months
- Catheter sepsis experienced within the last 3 months
- Known heart failure or active coronary disease
- Known celiac disease
- Radiation enteritis, scleroderma, coeliac disease, refractory or tropical sprue, diabetes
- Alcohol or drug abuse within the last 12 months
- Inadequate hepatic function as defined by: ALT and ASAST both \>2.0X ULN; TBL \>2X ULN; or ALP \>2.5X ULN
- Inadequate renal function as defined by serum creatinine \<0.7 or \>1.3 mg/dL (in men) and \<0.6 or \>1.1 mg/dL in women.
- Personal or family history of medullary thyroid cancer.
- History of pancreatitis.
- Any patient who receives insulin in their PS.
- Any hospitalization within 1 month before screening visit
- Systemic corticosteroids, methotrexate, cyclosporine, tacrolimus, sirolimus, infliximab, or mycophenolate mofetil (CellCept®) within 30 days of screening
- Any use of growth hormone, or growth factors such as native GLP-2 or GLP-2 analog (teduglutide) within the last 3 months
- Use of antibiotics within the last 30 days
- Subject not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements.
Key Trial Info
Start Date :
June 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04379856
Start Date
June 23 2020
End Date
December 31 2020
Last Update
November 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Facility One
Los Angeles, California, United States, 90048